Physician profile
Allen M Ferrucci
NPI 1578721072
$12,508.66
in general payments reported to CMS, 2019-2025
21 companies · $1,725 in 2025
The $1,725 reported for 2025 was more than what a typical Foot and Ankle Surgery provider received nationally (typical 2025 total: $1,200).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $633 · 2020: $415 · 2021: $453 · 2022: $4,027 · 2023: $4,236 · 2024: $1,019 · 2025: $1,725.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,875 · Royalty Or License: $2,165 · Food and Beverage: $940.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,875.00 |
| Royalty Or License | $2,164.66 |
| Food and Beverage | $940.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gramercy Extremity Orthopedics LLC | $10,136.82 | 2019-2025 | |
| Horizon Therapeutics Plc | $907.15 | 2019-2022 | |
| Stryker Corporation | $386.63 | 2019-2025 | Variax, Infinity Adaptis, Invision |
| Depuy Synthes Sales INC. | $345.60 | 2019-2025 | Orthovisc, Monovisc, Peak |
| Smith+Nephew, INC. | $244.86 | 2019-2024 | Panta 2, Vlp Mini-Mod, Cadence |
| Paragon 28, INC. | $74.45 | 2019 | |
| Endo USA, INC. | $73.54 | 2024-2025 | Xiaflex |
| Zimmer Biomet Holdings, INC. | $45.06 | 2021 | |
| Pacira Therapeutics, INC. | $41.88 | 2019 | |
| Bioventus LLC | $39.54 | 2023-2025 | Other, Exogen Ultrasound Bone Healing System |
| Orthofix Medical, INC. | $30.61 | 2021-2025 | Physio-Stim |
| Celularity INC. | $25.58 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $24.22 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $21.82 | 2025 | |
| Pacira Pharmaceuticals Incorporated | $20.69 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Treace Medical Concepts, INC. | $19.06 | 2025 | |
| Dynasplint Systems INC. | $18.77 | 2024 | Dynasplint |
| Innovation Technologies INC | $17.18 | 2025 | Irrisept |
| Ferring Pharmaceuticals INC. | $12.88 | 2023 | Euflexxa |
| Zimvie INC. | $12.76 | 2023 | |
| Globus Medical, INC. | $9.56 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$1,800,000.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allen Ferrucci listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.